Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 151

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 151
---
 tests are authorized for marketing by the FDA, the agency could limit the test’s indications for use,
which may significantly limit the market for that product and may adversely affect DiamiR’s business and financial condition.

<div align='center'>79</div>

DiamiR has a limited operating history, which makes it difficult to predict future prospects and financial performance.

Substantially all of DiamiR’s operations are conducted through
its wholly-owned subsidiary, DiamiR LLC, which started operation in September 2009. DiamiR has been operating as a consolidated company
since October 1, 2014. Due to this limited operating history, it may be difficult to evaluate DiamiR’s business prospects and
future financial performance. As of the date of this filing, DiamiR has not yet generated revenues from its products. There is no guarantee
that DiamiR will be able to generate any significant revenues. DiamiR faces numerous risks and uncertainties in the competitive markets.
In particular, DiamiR has not proven that it can:

| ● | maintain relationships with key customers and strategic partners                  
 that will be necessary to optimize the market value of its products and services; |

| ● | successfully identify and respond to emerging trends in DiamiR’s 
 market areas;                                                    |

| ● | raise sufficient capital in the public and/or private markets; 
 or                                                             |

| ● | respond effectively to competitive pressures. |

DiamiR’s ability to generate revenue and achieve profitability
is dependent on its ability to complete the development of its product candidates, obtain necessary regulatory approvals, and have its
products under development manufactured and successfully marketed, of which there can be no guarantee. Although DiamiR has received revenue
in the past from providing testing services to life sciences companies, and may again in the future, DiamiR cannot be certain that such
services will bring sufficient revenue to support its operation and R&D. Thus, DiamiR may not be able to generate a profit until
its product candidates become profitable.

There is substantial doubt about DiamiR’s ability to continue as a going concern.

DiamiR’s auditors have indicated in their audit opinion there
is substantial doubt as to DiamiR’s ability to continue as a going concern in their audit report on its audited financial statements
for the year ended May 31, 2025. Since its inception in December 2009, DiamiR’s operations have been funded through capital
contributions of its founders as well as grant funding